Daniel Egle

机构：Innsbruck Medical University, Universität Innsbruck, Comprehensive Cancer Center Vienna, Arbeitsgemeinschaft medikamentöse Tumortherapie, Austrian Breast & Colorectal Cancer Study Group, Medical University of Vienna · ORCID：0000-0003-0283-8176

发表论文 295 篇 · 总被引 6275 次 · h-index 32

代表论文

• Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13) (2025 · Annals of Oncology · 被引 11)
• VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer (2026 · Journal of Clinical Oncology · 被引 9)
• New Perspectives in the Management of Triple-Negative Breast Cancer (2025 · Breast Care · 被引 4)
• Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial. (2025 · Journal of Clinical Oncology · 被引 4)
• Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial (2026 · Annals of Oncology · 被引 2)
• Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial (2026 · npj Breast Cancer · 被引 2)